• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $KURA

    Kura Oncology Inc.

    Subscribe to $KURA
    $KURA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer in the United States. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidates are tipifarnib, an orally bioavailable inhibitor of farnesyl transferase that is in Phase II clinical trials for the treatment of solid tumors and hematologic indications; and KO-539, a small molecule inhibitor of the menin-Lysine K-specific Methyltransferase 2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia. Kura Oncology, Inc. was founded in 2014 and is headquartered in San Diego, California.

    IPO Year:

    Exchange: NASDAQ

    Website: kuraoncology.com

    Peers

    $RNA
    $CRDF
    $CLVS
    $ZIOP
    $IKNA

    Recent Analyst Ratings for Kura Oncology Inc.

    DatePrice TargetRatingAnalyst
    2/6/2025Buy → Neutral
    BTIG Research
    10/24/2024$27.00Buy
    UBS
    10/14/2024$26.00 → $19.00Buy → Hold
    Stifel
    12/22/2023$26.00Buy
    Mizuho
    8/11/2023$31.00Buy
    BofA Securities
    7/27/2023$10.50Sector Perform
    Scotiabank
    5/17/2023$31.00Buy
    BTIG Research
    1/31/2023$25.00Buy
    Stifel
    7/12/2022$30.00Overweight
    Cantor Fitzgerald
    2/25/2022$25.00 → $27.00Outperform
    Credit Suisse
    See more ratings

    Kura Oncology Inc. Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Kura Oncology to Participate in Bank of America Securities Healthcare Conference

      SAN DIEGO, May 06, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in Bank of America Securities 2025 Healthcare Conference. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a fireside chat at 6:00 p.m. ET / 3:00 p.m. PT on May 13, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. About Kura Oncology Kura Oncology is a clinical-stage biopharm

      5/6/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on May 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 433,950 shares of common stock to sixteen (16) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listi

      5/2/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Announces First Patients Dosed in Phase 1 Combination Trial of Ziftomenib for the Treatment of Advanced GIST

      – Phase 1 dose-escalation study to evaluate ziftomenib in combination with imatinib in patients with advanced GIST after imatinib failure – – Combination of ziftomenib and imatinib shows robust and durable antitumor activity in imatinib-sensitive and imatinib-resistant GIST preclinical models – SAN DIEGO, April 28, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that the first patients have been dosed in KOMET-015, a Phase 1 clinical trial of ziftomenib, the Company's potent and selective, oral investigational menin inhibitor, in p

      4/28/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report First Quarter 2025 Financial Results

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

      4/24/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Kyowa Kirin Announce Submission of New Drug Application for Ziftomenib to FDA

      SAN DIEGO and TOKYO, April 08, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")), and Kyowa Kirin Co., Ltd. (TSE: 4151, "Kyowa Kirin"), today announced Kura submitted a New Drug Application (NDA) for ziftomenib, a highly selective, once-daily, oral, investigational menin inhibitor, for the treatment of adult patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) with a nucleophosmin 1 (NPM 1) mutation to the U.S. Food and Drug Administration (FDA) on March 31, 2025. Ziftomenib has received Breakthrough Therapy, Fast Track, and Orphan Drug Designations. The FDA has a 60-day filing review period to determine whether the NDA is complete and accepted for rev

      4/8/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, April 04, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on April 1, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 79,500 shares of common stock to four (4) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listin

      4/4/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Participate in Stifel Targeted Oncology Forum

      SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the Stifel 2025 Virtual Targeted Oncology Forum. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 10:30 a.m. ET / 7:30 a.m. PT on April 8, 2025. A live audio webcast of the fireside chat will be available in the Investors section of Kura's website at www.kuraoncology.com, with an archived replay following the event. About Kura Oncology Kura Oncology is a clinical-stag

      4/1/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Announces Preclinical Data for KO-2806 Selected for Oral Presentation at the 2025 AACR Annual Meeting

      – Oral presentation to highlight preclinical data further supporting combination of KO-2806 with TKIs in ccRCC – – Company expects to present data from the Phase 1 FIT-001 trial evaluating KO-2806 and cabozantinib in patients with RCC in 2H 2025 – SAN DIEGO, March 26, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that an abstract containing preclinical data for KO-2806, the Company's next-generation farnesyl transferase inhibitor (FTI), in combination with cabozantinib, a tyrosine kinase inhibitor (TKI), in clear cell renal cell c

      3/26/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

      SAN DIEGO, March 07, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that on March 3, 2025, the Compensation Committee of the Company's Board of Directors (the "Compensation Committee") granted inducement awards consisting of nonstatutory stock options to purchase 190,000 shares of common stock to six (6) new employees under the Company's 2023 Inducement Option Plan, as amended. The Compensation Committee approved the stock options as an inducement material to such employees' employment in accordance with Nasdaq Listin

      3/7/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Kura Oncology Inc.

      SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

      12/5/24 6:55:37 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:31:29 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Kura Oncology Inc.

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      11/14/24 4:32:22 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Kura Oncology Inc.

      SC 13G - Kura Oncology, Inc. (0001422143) (Subject)

      5/2/24 4:34:30 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      2/14/24 5:58:09 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      2/14/24 9:39:25 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      2/13/24 5:23:14 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      2/12/24 5:33:12 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      1/24/24 2:27:13 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Kura Oncology Inc. (Amendment)

      SC 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      1/23/24 9:12:04 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. SEC Filings

    See more
    • SEC Form 10-Q filed by Kura Oncology Inc.

      10-Q - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:15:19 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      5/1/25 4:10:11 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEF 14A filed by Kura Oncology Inc.

      DEF 14A - Kura Oncology, Inc. (0001422143) (Filer)

      4/11/25 4:50:53 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 144 filed by Kura Oncology Inc.

      144 - Kura Oncology, Inc. (0001422143) (Subject)

      3/21/25 4:21:02 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-8 filed by Kura Oncology Inc.

      S-8 - Kura Oncology, Inc. (0001422143) (Filer)

      2/28/25 4:15:38 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-K filed by Kura Oncology Inc.

      10-K - Kura Oncology, Inc. (0001422143) (Filer)

      2/28/25 4:01:36 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      2/26/25 4:05:09 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Kura Oncology Inc.

      SCHEDULE 13G/A - Kura Oncology, Inc. (0001422143) (Subject)

      2/13/25 8:57:46 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Kura Oncology Inc.

      8-K - Kura Oncology, Inc. (0001422143) (Filer)

      2/5/25 4:13:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SCHEDULE 13G filed by Kura Oncology Inc.

      SCHEDULE 13G - Kura Oncology, Inc. (0001422143) (Subject)

      2/4/25 8:09:30 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Hasnain Faheem exercised 22,682 shares at a strike of $6.32 and sold $181,456 worth of shares (22,682 units at $8.00) (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      3/24/25 4:33:39 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, Finance & Accounting Doyle Thomas James sold $38,958 worth of shares (4,949 units at $7.87), decreasing direct ownership by 5% to 88,193 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:54:15 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Leoni Mollie sold $39,068 worth of shares (4,963 units at $7.87), decreasing direct ownership by 5% to 88,253 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:39:01 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Legal Officer Bair Teresa Brophy sold $57,315 worth of shares (7,281 units at $7.87), decreasing direct ownership by 6% to 107,948 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:38:49 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Operating Officer Ford Kathleen sold $14,303 worth of shares (1,817 units at $7.87), decreasing direct ownership by 8% to 21,367 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:38:36 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Scientific Officer Burrows Francis sold $17,051 worth of shares (2,166 units at $7.87), decreasing direct ownership by 9% to 20,705 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:38:25 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Commercial Officer Powl Brian T. sold $12,461 worth of shares (1,583 units at $7.87), decreasing direct ownership by 3% to 59,667 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/28/25 8:38:11 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Medical Officer Leoni Mollie was granted 46,250 shares, increasing direct ownership by 98% to 93,216 units (SEC Form 4)

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/7/25 5:48:07 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Leoni Mollie claimed ownership of 46,966 shares (SEC Form 3)

      3 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/7/25 5:42:51 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Burrows Francis

      4 - Kura Oncology, Inc. (0001422143) (Issuer)

      1/7/25 5:32:43 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. Financials

    Live finance-specific insights

    See more
    • Kura Oncology Reports First Quarter 2025 Financial Results

      – NDA submitted in 1Q 2025 for ziftomenib for the treatment of adult patients with relapsed or refractory AML with an NPM1 mutation – – Data from Phase 1b/2 registration-directed trial of ziftomenib selected for oral presentation at ASCO Annual Meeting – – $45.0 million milestone payment earned for NDA submission under collaboration agreement with Kyowa Kirin – – First patients dosed in Phase 1 trial of ziftomenib plus imatinib in GIST – – $703.2 million in pro forma cash, together with anticipated collaboration agreement payments, expected to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference call today at 4:

      5/1/25 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report First Quarter 2025 Financial Results

      SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report first quarter 2025 financial results after the close of U.S. financial markets on Thursday, May 1, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 245-3047 for domestic callers and (203) 518-9765 for international callers and entering the conference ID: KURAQ1. A live webcast and

      4/24/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Fourth Quarter and Full Year 2024 Financial Results

      – KOMET-001 registrational trial in R/R NPM1-mutant AML achieved primary endpoint – – Alignment reached with FDA and EMA on key aspects of the KOMET-017 protocol including use of MRD-negative CR endpoint for potential U.S. accelerated approval pathway in frontline intensive chemotherapy trial – – Topline MRD-negative CR results from KOMET-017-IC Phase 3 trial anticipated in 2028 – – Multiple data presentations for ziftomenib and pipeline programs expected throughout 2025 – – $727.4 million in cash, together with anticipated collaboration agreement payments, to support ziftomenib commercialization through the frontline AML combination setting – – Management to host webcast and conference

      2/26/25 4:03:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report Fourth Quarter and Full Year 2024 Financial Results

      SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the "Company") (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report fourth quarter and full year 2024 financial results after the close of U.S. financial markets on Wednesday, February 26, 2025. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 579-2543 for domestic callers and (785) 424-1789 for international callers and entering the confer

      2/19/25 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

      – KOMET-001 registrational trial in R/R NPM1-m AML achieved primary CR/CRh endpoint; topline data submitted for presentation at an upcoming medical meeting – – NDA submission for ziftomenib on track for 2Q 2025 – – Registrational KOMET-017-IC trial of intensive chemotherapy combination will assess MRD negative CR and EFS as dual-primary endpoints to support potential U.S. accelerated approval and full approval – – Registrational KOMET-017-NIC trial of venetoclax / azacitidine combination will assess CR and OS as dual-primary endpoints to support potential U.S. accelerated approval and full approval – – KOMET-017-IC and NIC Phase 3 trials expected to initiate in 2H 2025 – – Multiple clin

      2/5/25 4:01:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Kyowa Kirin Report Positive Combination Data for Ziftomenib at American Society of Hematology Annual Meeting

      – Interim analysis from Phase 1a portion of KOMET-007 shows 100% CR rate in NPM1-m and 83% CR rate in KMT2A-r 1L adverse risk AML with 7+3 – – 100% of 1L NPM1-m and 96% of 1L KMT2A-r AML patients alive as of data cutoff with median follow-up of 31 and 19 weeks, respectively – – Promising clinical activity in R/R NPM1-m and KMT2A-r AML with ven/aza, including ven-experienced patients – – Ziftomenib generally well tolerated in combination with standards of care at all dose levels studied – – Kura Oncology to host virtual investor event today at 8:00 a.m. ET – SAN DIEGO and TOKYO, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA, "Kura")) and Kyowa Kirin Co., Ltd. (TSE:

      12/9/24 7:00:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias

      – Kura to receive a $330 million upfront payment and up to $1.2 billion in total milestone payments, including $420 million in near-term milestone payments and opt-in right for solid tumors – – Companies to jointly develop and commercialize ziftomenib; 50/50 profit share in the U.S.; Kura to lead U.S. development and commercial activities and book sales; Kyowa Kirin has exclusive commercialization rights outside the U.S. – – Companies to jointly pursue broad development program targeting acute leukemias, including frontline indications, combinations with targeted therapies and post-transplant maintenance setting – – Kura anticipates collaboration funding along with current cash balance to

      11/20/24 5:00:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Third Quarter 2024 Financial Results

      – Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The Lancet Oncology – – Data from 100 patients in Phase 1a dose-escalation study of ziftomenib combined with ven/aza in R/R AML and 7+3 in 1L adverse risk AML to be presented at ASH – – Phase 1b expansion study of ziftomenib in combination with standards of care now enrolling at 600 mg in all cohorts – – Preclinical data support opportunity for ziftomenib in GIST; proof-of-concept study expected to begin in 1H 2025 – – First patient dosed in study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $455.3 million in cash, cas

      11/7/24 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology to Report Third Quarter 2024 Financial Results

      SAN DIEGO, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced that it will report third quarter 2024 financial results after the close of U.S. financial markets on Thursday, November 7, 2024. Kura's management will host a webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT that day to discuss the financial results and provide a corporate update. The live call may be accessed by dialing (800) 225-9448 for domestic callers and (203) 518-9708 for international callers and entering the conference ID: KURAQ3. A live webcast a

      10/31/24 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Reports Second Quarter 2024 Financial Results

      – Topline data from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025 – – Breakthrough Therapy Designation granted for ziftomenib in R/R NPM1-mutant AML – – Data from 100 patients in KOMET-007 trial of ziftomenib in combination with ven/aza and 7+3 expected in Q4; Phase 1b expansion study in 1L AML now enrolling – – Investigational New Drug (IND) application cleared for ziftomenib in GIST – – Preclinical data at ADA support potential for menin inhibitor in diabetes – – First patient dosed in study of KO-2806 and adagrasib in KRASG12C-mutated NSCLC – – $491.5 million in cash, cash equivalents and investments provide runway into 2027 – – Management

      8/8/24 4:05:00 PM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. Leadership Updates

    Live Leadership Updates

    See more
    • Cartography Announces Appointment of Troy Wilson, Ph.D., J.D., to its Board of Directors

      – Industry veteran to serve as independent director, strengthening the board and bringing extensive leadership, executive and governance experience to Cartography as it builds out its oncology platform and pipeline - Cartography Biosciences, Inc., an oncology company advancing a pipeline of antibody therapeutics that more precisely target tumors, today announced the appointment of Troy E. Wilson, Ph.D., J.D., as an independent director. Dr. Wilson, a 25-year veteran of the biopharma industry, is President, CEO and co-founder of Kura Oncology (NASDAQ:KURA) and has served as chairman of its Board of Directors since it was founded in 2014. "We are delighted to have attracted a true industry

      10/29/24 8:00:00 AM ET
      $AMAM
      $KURA
      $RNA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
      Biotechnology: Pharmaceutical Preparations
    • Kura Oncology Appoints Michael Vasconcelles, M.D., to Board of Directors

      SAN DIEGO, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Michael Vasconcelles, M.D., to its Board of Directors. Dr. Vasconcelles is an accomplished biopharmaceutical executive with more than 25 years of oncology drug development experience and industry leadership. "On behalf of our Board and leadership team, we are delighted to have Mike join our Board of Directors," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "His extensive experience in R&D and regulatory aff

      9/17/24 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Brian Powl as Chief Commercial Officer

      SAN DIEGO, Aug. 14, 2023 (GLOBE NEWSWIRE) --  Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Brian Powl as Chief Commercial Officer. Mr. Powl joins Kura with more than 20 years of experience in building commercial brands in hematology and oncology, with a focus on developing and executing patient-focused strategies across sales, marketing and market access for global biotech and pharmaceutical products. "Brian is an accomplished leader with a strong track record in building successful commercial organizations and driving global commercial

      8/14/23 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

      WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ:VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. "As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team" said Jonathan Violin, Ph.D., Viridian Therapeutics' President and CEO. "Carrie's extensive experience in a wide range of operational activities supporting product development and approval will be tremendously valuable to our expanding

      6/23/22 7:00:00 AM ET
      $GSK
      $KURA
      $VRDN
      $XFOR
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Medical Specialities
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Celularity Appoints Industry Leader Diane Parks to its Board of Directors

      FLORHAM PARK, N.J., June 03, 2022 (GLOBE NEWSWIRE) -- Celularity Inc. (NASDAQ:CELU) ("Celularity"), a clinical-stage biotechnology company developing placental-derived off-the-shelf allogeneic cell therapies, today announced the appointment of Diane Parks to its Board of Directors. Ms. Parks, an executive with deep experience in the commercialization of novel immuno-oncology therapies, has led the successful launch of numerous hematology and cancer therapies at large pharmaceutical and biotech companies, including Kite Pharma, Inc. (now part of Gilead Sciences, Inc.), Amgen Inc., and Genentech, Inc. (now part of Roche Holdings, Inc.). "It is with great pleasure we welcome Diane to the Cel

      6/3/22 8:00:00 AM ET
      $CALT
      $CELU
      $CTIC
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Teresa Bair as Chief Legal Officer

      SAN DIEGO, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Teresa Bair as Chief Legal Officer and Corporate Secretary. Ms. Bair joins Kura with more than 25 years of combined in-house and law firm experience, most recently as General Counsel at Athenex. "On behalf of our board and senior leadership team, we want to extend a warm welcome to Teresa," said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology. "She brings a breadth of expertise across a range of legal and business

      10/18/21 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • PepGen Announces New Additions to Leadership Team and Board of Directors

      New appointments follow PepGen's recent $112.5 million crossover financing to advance therapies for neuromuscular diseases PepGen is rapidly advancing lead programs in Duchenne muscular dystrophy and myotonic dystrophy type 1 to the clinic and growing its team in Boston, MA. BOSTON, Aug. 31, 2021 (GLOBE NEWSWIRE) -- PepGen, Inc., a company advancing next-generation oligonucleotide therapies for neuromuscular diseases, today announced that Heidi Henson will join PepGen's Board of Directors. The company also announced the promotion of Jane Larkindale, Ph.D., to Vice President of Clinical Science. "As we continue to evolve our team of PepGen Pioneers, I am delighted to announce the p

      8/31/21 7:00:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology Appoints Carol Schafer to Board of Directors

      SAN DIEGO, June 04, 2021 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced the appointment of Wall Street veteran Carol Schafer to its board of directors, effective June 3, 2021. Ms. Schafer has more than 25 years of experience in healthcare investment banking, most recently as Vice Chair of Equity Capital Markets at Wells Fargo Securities. “Carol brings a wealth of experience as a trusted strategic and financial advisor to the leadership teams of growing biopharmaceutical companies,” said Troy Wilson, Ph.D., J.D., President and Chief Exe

      6/4/21 7:30:00 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    Kura Oncology Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Kura Oncology downgraded by BTIG Research

      BTIG Research downgraded Kura Oncology from Buy to Neutral

      2/6/25 7:53:07 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • UBS initiated coverage on Kura Oncology with a new price target

      UBS initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $27.00

      10/24/24 6:23:30 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology downgraded by Stifel with a new price target

      Stifel downgraded Kura Oncology from Buy to Hold and set a new price target of $19.00 from $26.00 previously

      10/14/24 7:36:13 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mizuho initiated coverage on Kura Oncology with a new price target

      Mizuho initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $26.00

      12/22/23 7:26:15 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BofA Securities initiated coverage on Kura Oncology with a new price target

      BofA Securities initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $31.00

      8/11/23 7:16:37 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Scotiabank initiated coverage on Kura Oncology with a new price target

      Scotiabank initiated coverage of Kura Oncology with a rating of Sector Perform and set a new price target of $10.50

      7/27/23 7:27:31 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Kura Oncology with a new price target

      BTIG Research initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $31.00

      5/17/23 7:24:53 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Stifel initiated coverage on Kura Oncology with a new price target

      Stifel initiated coverage of Kura Oncology with a rating of Buy and set a new price target of $25.00

      1/31/23 6:13:24 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Kura Oncology with a new price target

      Cantor Fitzgerald initiated coverage of Kura Oncology with a rating of Overweight and set a new price target of $30.00

      7/12/22 7:30:34 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on Kura Oncology with a new price target

      Credit Suisse reiterated coverage of Kura Oncology with a rating of Outperform and set a new price target of $27.00 from $25.00 previously

      2/25/22 10:56:08 AM ET
      $KURA
      Biotechnology: Pharmaceutical Preparations
      Health Care